Map the disrupted ecosystem
Multi-omics profiling identifies which ecological functions are absent in disease and which strains restore them.
Invest · Partner
Invest in the future of gut medicine.
GutRecover is building a defined-consortium platform to restore the gut ecosystem — addressing large, underserved indications, led by recurrent C. difficile infection and ulcerative colitis, with a Phase 1-ready lead program and a proprietary strain library.
For investors
The GutRecover investor presentation
A concise overview of the platform, pipeline, market opportunity, and the team building defined microbiome medicine. Watch the walkthrough or download the deck.
01 — Why invest
A defensible position at an inflection point
GutRecover combines a proprietary strain library, a multi-omics discovery platform, and pharmaceutical-grade manufacturing — the components required to build a durable microbiome therapeutics company.
- Proprietary strain library150+ characterised strains accumulated through structured isolation campaigns, maintained under strict access controls.
- Defined consortia — no donor materialEvery candidate is a precisely defined community of characterised strains, enabling pharmaceutical-grade reproducibility and regulatory clarity.
- Multi-omics discovery engineMetagenomics, metatranscriptomics, and metabolomics turn ecosystem data into reproducible, biomarker-driven medicine.
- Phase 1-ready lead programGR-101 is IND-enabling for recurrent C. difficile infection — the same modality and indication as the first FDA-approved defined consortia — with two further programs behind it.1,2
- Growing IP portfolioComposition-of-matter and platform-method filings across key jurisdictions, anchored in a defensible discovery engine.
- Backed by QADR BiotechnologyGutRecover advances as the therapeutic arm of the QADR group, with R&D and early manufacturing infrastructure in place.
// Strain-library and program counts are internal company metrics; GR-101 is shown at its honest IND-enabling / Phase 1-ready stage.
02 — Platform
A discovery platform, not a single product
The same multi-omics engine that produced GR-101 generates the rest of the pipeline — de-risking each successive program and compounding the value of the strain library.
Engineer the consortium
Candidate consortia are designed against biomarker targets whose normalisation correlates with clinical resolution.
Earn each claim
Germ-free models and pre-specified endpoints precede human studies — evidence before advancement, every time.
03 — Market opportunity
A large, underserved market
Microbiome-driven disease spans gastrointestinal infection, inflammatory disease, and immune dysregulation — indications where current therapies fall short and defined consortia offer a differentiated approach. The first defined and standardised microbiome therapies reached FDA approval in 2022–2023, validating both the modality and the commercial path.1,8
C. difficile infections · US / yr
~500K
First recurrences · US / yr
~83K
Patients with at least one recurrence — GR-101's target population.25
Sources: US C. difficile burden — CDC Emerging Infections Program / NEJM (Lessa 2015; Guh 2020); US ulcerative colitis prevalence — Lewis et al. 2023. Full citations in Publications.
04 — Pipeline
Three programs from one platform
A staged portfolio across distinct indications, anchored by a clinical-stage lead program.
GR-101
Recurrent C. difficile infection
Phase 1-ready
GR-201
Ulcerative colitis
Preclinical
GR-301
Gut–immune axis (undisclosed)
Discovery
05 — At a glance
What makes GutRecover different
Defined-consortium platform
Reproducible, characterised communities of bacteria — not donor-derived preparations — built for regulatory and clinical credibility.
Multi-omics discovery
A repeatable pipeline from ecosystem data to candidate consortium, compounding the value of every program and every strain.
Experienced operators
Microbiology, clinical development, manufacturing, and company-building experience across three operating locations.
IP & manufacturing
Composition and method filings plus controlled fermentation manufacturing — a defensible position that is difficult to replicate.
06 — Optimising the funnel
A discovery funnel built to de-risk
Each stage is designed to fail fast and cheaply — concentrating capital on the candidates most likely to succeed in the clinic.
01
Identify
Real-world, multi-omics data reveal the causes of dysbiosis-driven disease, narrowing the search before any animal work begins.
02
Develop
Characterised strains from the proprietary library are assembled into ecologically rational consortia and tested against biomarker targets.
03
Optimise
Pre-specified endpoints and controlled manufacturing carry only the highest-probability candidates into clinical development.
07 — Events & webcasts
Upcoming events
Where to meet the GutRecover team and hear program updates.
09 — Corporate governance
Built on credible structure
GutRecover operates with the governance discipline expected of a clinical-stage therapeutics company, scaled appropriately to its development phase.
Board of Directors
Founder-led, advisor-supported
Chaired by the Founder & CEO, with independent scientific and commercial directors to be appointed as the company scales.
Scientific oversight
Scientific Advisory Board
External counsel in microbiome science, gastroenterology, and regulatory science guides program decisions. See the SAB →
Governance documents
Policies & charters
Board charter, code of conduct, and committee mandates available to qualified investors on request.
10 — Investor relations
Let's talk.
For the investor presentation, partnership inquiries, or to be added to our investor update list, reach the team directly.
To receive investor updates, email investors@grtherapeutics.com →